DNA

Ginkgo Bioworks Holdings, Inc. Stock Price

NYSE:DNA Community·US$885.1m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 56 Fair Values set on narratives written by author

DNA Share Price Performance

US$16.14
7.81 (93.76%)
0.9% overvalued intrinsic discount
US$16.00
Fair Value
US$16.14
7.81 (93.76%)
0.9% overvalued intrinsic discount
US$16.00
Fair Value
Price US$16.14
AnalystHighTarget US$16.00
AnalystConsensusTarget US$11.33
AnalystLowTarget US$9.00

DNA Community Narratives

AnalystHighTarget·Updated
Fair Value US$16 0.9% overvalued intrinsic discount

Automation And AI Expansion Will Advance Lab Markets Despite Risks

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$11.33 42.4% overvalued intrinsic discount

Life Sciences Automation Will Stagnate Amid Regulatory Challenges

0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$9 79.3% overvalued intrinsic discount

Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent DNA News & Updates

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up

Oct 03
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 31% Price Boost Is Out Of Tune With Revenues

Jun 25
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 31% Price Boost Is Out Of Tune With Revenues

Ginkgo Bioworks Holdings, Inc. Key Details

US$230.8m

Revenue

US$48.5m

Cost of Revenue

US$182.3m

Gross Profit

US$497.5m

Other Expenses

-US$315.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-5.69
Gross Margin
78.99%
Net Profit Margin
-136.56%
Debt/Equity Ratio
0%

Ginkgo Bioworks Holdings, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

About DNA

Founded
2008
Employees
834
CEO
Jason Kelly
WebsiteView website
www.ginkgo.bio

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 7.7%
  • 1 Year: 17.9%
  • Year to Date: 14.9%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›